TP53 and pancreatic adenocarcinoma: For example, shorter overall survival has been demonstrated for patients with R273C-p53 in comparison with R273H-p53 mutation in breast cancer studies (Supplementary Fig. 6D, left), while the opposite was observed in multiple cancer cohorts, including non-small cell lung cancer, glioblastoma, pancreatic adenocarcinoma and ovarian cancer (Supplementary Fig. 6D, right).